The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
Open accessAbstract
Cytochrome P450 2B6 (CYP2B6) belongs to the minor drug metabolizing P450s in human liver. Expression is highly variable both between individuals and within individuals, owing to non-genetic factors, genetic polymorphisms, inducibility, and irreversible inhibition by many compounds. Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone. CYP2B6 is one of the most polymorphic CYP genes in humans and variants have been shown to affect transcriptional regulation, splicing, mRNA and protein expression, and catalytic activity. Some variants appear to affect several functional levels simultaneously, thus, combined in haplotypes, leading to complex interactions between substrate-dependent and -independent mechanisms. The most common functionally deficient allele is CYP2B6*6 [Q172H, K262R], which occurs at frequencies of 15 to over 60% in different populations. The allele leads to lower expression in liver due to erroneous splicing. Recent investigations suggest that the amino acid changes contribute complex substrate-dependent effects at the activity level, although data from recombinant systems used by different researchers are not well in agreement with each other. Another important variant, CYP2B6*18 [I328T], occurs predominantly in Africans (4-12%) and does not express functional protein. A large number of uncharacterized variants are currently emerging from different ethnicities in the course of the 1000 Genomes Project. The CYP2B6 polymorphism is clinically relevant for HIV-infected patients treated with the reverse transcriptase inhibitor efavirenz, but it is increasingly being recognized for other drug substrates. This review summarizes recent advances on the functional and clinical significance of CYP2B6 and its genetic polymorphism, with particular emphasis on the comparison of kinetic data obtained with different substrates for variants expressed in different recombinant expression systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., & Negishi, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6043 · Cited by 668
Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Hulgan, T., Marzolini, C., & Acosta, E. P. (2004) · PubMed · Cited by 627
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 571
Self-citationInhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Chang, T. K. H., Weber, G. F., Crespi, C. L., & Waxman, D. J. (1993) · PubMed · Cited by 545
Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L., Fackenthal, J. D., Rogan, P. K., Ring, B., Wrighton, S. A., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054866 · Cited by 400
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Cited by
BiT age: A transcriptome‐based aging clock near the theoretical limit of accuracy
Meyer, D. H., & Schumacher, B. (2021) · Aging Cell · doi:10.1111/acel.13320 · Cited by 165
Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity
Toce, M. S., Chai, P. R., Burns, M. M., & Boyer, E. W. (2018) · Journal of Medical Toxicology · doi:10.1007/s13181-018-0685-1 · Cited by 90
Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance
Rao, L. K., Flaker, A. M., Friedel, C. C., & Kharasch, E. D. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001392 · Cited by 67
Petzold, A., & Hassanin, A. (2020) · PLOS ONE · doi:10.1371/journal.pone.0217956 · Cited by 60
Residual Cdk1/2 activity after DNA damage promotes senescence
Müllers, E., Silva Cascales, H., Burdova, K., Macurek, L., & Lindqvist, A. (2017) · Aging Cell · doi:10.1111/acel.12588 · Cited by 56
Metadata
- Authors
- Zanger, U. M., & Klein, K.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 24-24
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W1987178620
- Cited by
- 345
- References
- 121
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. https://app.cochat.ai/papers/10.3389/fgene.2013.00024
- The paper
- Zanger, U. M., & Klein, K. (2013). Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Frontiers in Genetics. https://doi.org/10.3389/fgene.2013.00024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.